Parvovirus B19 is the causative agent of "fifth disease" of childhood. It h
as been implicated in a variety of conditions, including unsuccessful pregn
ancy and rheumatoid arthritis, and is a potential contaminant of blood prod
ucts, There has been little study of immunity to parvovirus B19, and the ex
act nature of the protective humoral and cell-mediated immune response is u
nclear. Immune responses to purified virus capsid proteins, VP1 and VP2, we
re examined from a cohort of recently infected children and compared with r
esponses from long-term convalescent volunteers. The results demonstrate th
at antibody reactivity is primarily maintained against conformational epito
pes in VP1 and VP2. The unique region of VPI appears to be a major target f
or cell-mediated immune responses, particularly in recently infected indivi
duals. We confirm that antibody reactivity against linear epitopes of VP2 i
s lost shortly after infection but find no evidence of the proposed phenoty
pic switch in either the subclass of parvovirus B19-specific antibody or th
e pattern of cytokine production by antigen-specific T cells. The dominant
subclass of specific antibody detected from both children and adults was im
munoglobulin G1. No evidence was found for interleukin 4 (IL-4) or IL-5 pro
duction by isolated lymphocytes from children or adults, In contrast, lymph
ocytes from convalescent adults produced a typical type 1 response associat
ed with high levels of IL-2 and gamma interferon (IFN-gamma). However, we o
bserved a significant (P < 0.001) deficit in the production of IFN-gamma in
response to VP1 or VP2 from lymphocytes isolated from children. Taken toge
ther, these results imply that future parvovirus B19 vaccines designed for
children will require the use of conformationally preserved capsid proteins
incorporating Th1 driving adjuvants. Furthermore, these data suggest novel
mechanisms whereby parvovirus B19 infection may contribute to rheumatoid a
rthritis and unsuccessful pregnancy.